BACKGROUND: Gamma-glutamyl transferase (gamma-GT) is an enzyme present in the cell membranes, which is used as a new biomarker in prediction of inflammation, myocardial infarction, stroke, and cardiac death. The objective of this study was to investigate the relationship between serum levels of gamma-GT and cardiovascular disease in subjects with COPD and the correlation between serum gamma-GT level and degree of the limitation of air flow in COPD. METHODS: A total of 70 subjects (46.1%) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) A-B and normal function of the liver and biliary tract (mean age [IQR] 59 [51.75−70] y; 77.1% men) and 82 subjects (53.9%) with GOLD C-D (mean age [IQR] 59 [56 − 66] y; 79.3% men) participated. Serum levels of gamma-GT and C-reactive protein were measured and compared between the 2 groups. RESULTS: The serum level of gamma-GT was found to be significantly (P
CITATION STYLE
Bozkus, F., Dikmen, N., Sahin, H., & Samur, A. (2016). Serum gamma-glutamyl transferase activity as a potential novel cardiovascular biomarker in COPD. Respiratory Care, 61(11), 1465–1471. https://doi.org/10.4187/respcare.04800
Mendeley helps you to discover research relevant for your work.